Hormonal
Acute systemic hypoglycemia gates and enhances the entry and action of GLP-1 receptor agonists into the brain, leading to increased whole-body lipid oxidation.
If you are using a GLP-1 medication, maintaining stable or slightly lower blood glucose levels (without dangerous hypoglycemia) may help the drug work more effectively in your brain to burn fat. The drug's ability to enter the brain and boost fat burning is significantly enhanced when blood sugar is low, a mechanism that is often impaired in obesity.
we show that insulin-induced hypoglycemia enhances GLP-1R agonists entry in hypothalamus and area postrema, leading to enhanced whole-body fat oxidation.
Why this rating
Strong mechanistic evidence in mice with supporting human correlation data, though direct clinical translation requires caution.
Source
Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis
Wineke Bakker et al. · Cell Reports · 2022
DOI 10.1016/j.celrep.2022.111698
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →